View More Recent Stories

Aug 8, 2022 08:30AM Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022
Jun 13, 2022 08:04AM Inhibikase Therapeutics (IKT) Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review
Jun 13, 2022 08:00AM Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review
May 16, 2022 05:00PM Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
May 10, 2022 08:05AM Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
May 9, 2022 04:05PM Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
Apr 21, 2022 04:05PM Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
Apr 6, 2022 08:00AM Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022
Mar 31, 2022 05:00PM Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity
Mar 28, 2022 08:00AM Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors Summit
Mar 25, 2022 08:00AM Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022
Mar 23, 2022 08:00AM Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference
Mar 8, 2022 08:00AM Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference
Jan 5, 2022 08:30AM Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones
Nov 29, 2021 08:05AM Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease
Nov 15, 2021 05:30PM Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
Oct 27, 2021 08:05AM Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit
Oct 19, 2021 08:05AM Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
Oct 4, 2021 08:05AM Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease
Sep 23, 2021 08:08AM Inhibikase Therapeutics (IKT) Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy
Sep 23, 2021 08:05AM Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy
Sep 7, 2021 08:00AM Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
Aug 16, 2021 04:45PM Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
Jul 26, 2021 08:44AM Inhibikase Therapeutics (IKT) Received FDA Clearance to Begin Phase 1b Trial of IkT-148009 in Parkinson's Patients
Jul 26, 2021 08:42AM Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients
Jun 18, 2021 06:45PM Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock
Jun 16, 2021 06:21AM Inhibikase Therapeutics (IKT) Prices 15M Shares at $3
Jun 15, 2021 07:40PM Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock
May 17, 2021 04:05PM Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity
Apr 21, 2021 08:00AM Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum
Apr 1, 2021 08:00AM Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
View More Recent Stories